Augment Phase Iii Study: Lenalidomide/Rituximab (R2 ) Improved Efficacy Over Rituximab/Placebo in Relapsed/Refractory Follicular Patients Irrespective of Pod24 Status
Hematological Oncology - United Kingdom
doi 10.1002/hon.75_2629
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley